3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
2
Thoracic
1
Other hematologic neoplasm
1
Myeloid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
7
Cyclophosphamide
7
Surveys and Questionnaires
4
Filgrastim
4
aldesleukin
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Paclitaxel
3
Nivolumab
3
Methods
3
Flow Cytometry
3
Early Intervention, Educational
3
valspodar
2
sargramostim
2
fludarabine
2
atezolizumab
2
Therapeutics
2
Stem Cell Factor
2
Sirolimus
2
Methylprednisolone
2
Melphalan
2
Ipilimumab
2
Interleukin-2
2
Immunologic Techniques
2
Exercise
2
Etoposide
2
Epoetin Alfa
2
Educational Status
2
Drug Therapy
2
Data Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Tinzaparin
×
Breast
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled